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Bromocriptine is a dopamine receptor agonist known to cause hypotension and bradycardia in
several species. Five experiments were conducted to compare possible perturbations on heart rate
(HR) in horses after a brief (2 minutes) exercise bout when exposed to either short-term or longterm treatment with bromocriptine, cabergoline, or pergolide (all commonly used dopaminergic
agonists in horses) or sulpiride, a dopaminergic antagonist. For all experiments, prolactin was
measured as an indicator of drug efﬁcacy. Experiments 1 and 4 were conducted as a replicated Latin
square, whereas experiments 2, 3, and 5 were double split plot designs. Experiment 1 tested
changes in HR, adrenocorticotropin (ACTH), and growth hormone (GH) concentrations when
geldings were pretreated with 50 mg of bromocriptine 12 hours before exercise. Bromocriptine
pretreatment reduced (P < .05) the exercise-induced rise in HR and the ACTH and GH responses (P <
.05). Experiment 2 assessed the daily responses of HR to exercise after intramuscular administration
of 5 mg of cabergoline in vegetable oil, which diminished the rise in HR because of exercise for the
ﬁrst 2 days of the 7-day experiment. In experiment 3, daily feeding of 2g of pergolide top dressed
over sweet feed had no effect on HR in response to exercise. Similar results were seen in experiments 4 and 5, when horses were intravenously administered .01 mg/kg BW sulpiride in saline or
intramuscularly administered 1g of sulpiride dissolved in vegetable oil. Taken together, bromocriptine and cabergoline, but not pergolide or sulpiride, dampened the cardiac sympathetic
response to exercise, thus, lowering the HR.
© 2018 Elsevier Inc. All rights reserved.
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1. Introduction
The use of dopaminergic and antidopaminergic drugs is
commonplace in the equine industry to treat a variety of conditions. Sulpiride, a dopamine receptor antagonist, is used for the
advancement of ovulation in seasonally anestrous mares [1,2], in
addition to the induction of lactation in mares [3]. The dopaminergic agonists, cabergoline and pergolide, are notably indicated
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for the treatment of pituitary pars intermedia dysfunction (PPID)
and act by restoring dopaminergic action on melanotropes cells
in the pars intermedia, thereby diminishing hormonal output by
said cells [4]. Bromocriptine, another dopamine agonist, has been
studied in horses [5e7]; however, it is rarely used in horses
today.
Bromocriptine is currently applied in human medicine for the
treatment of hyperprolactinemia, Parkinson's disease, and Type II
diabetes, although it is noted to have hypotensive and bradycardic
effects. Hamed et al. [8] described a signiﬁcant decrease in blood
pressure, heart rate (HR), and total peripheral resistance after
anesthetized dogs were intravenously (IV) infused with 1 mg/kg/
min of bromocriptine for 20 minutes. Similar effects are reported in
humans [9e11], rats [12], and cats [13]. Because of the presence of
dopamine receptors in peripheral sympathetic neurons, activation
of presynaptic dopamine receptors can cause an inhibition of
sympathetic nerve function [14], thereby decreasing norepinephrine secretion [15]. Moreover, cardiac sympathetic function is
inhibited, causing impairments of cardiac acceleration even when
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an external stimulus is applied [14]. Similar results in cardiac activity have been reported for pergolide. Cavero et al [16] reported
bradycardia, decreased blood pressure, and decreased peripheral
resistance when anesthetized intact rats received 30 mg/kg IV. They
similarly concluded that pergolide inhibited the sympathetic tone
by stimulating dopamine receptors on peripheral nerves. Information on the sympatholytic effects for cabergoline is limited, and
no reports for any dopaminergic agonists have been reported on
the horse [17].
The present experiments were conducted to compare the
sympatholytic effects of bromocriptine administration in horses to
that stated in the literature and to determine if any effects are
shared with cabergoline and pergolide administration. This information would be useful for horse owners and veterinarians treating
PPID horses, as it is currently unknown whether dopaminergic
agonism affects HR in horses when concurrently engaged in
physical activities. This is important as changes in HR could
potentially alter a horse's performance. An additional two experiments were conducted to determine if antidopaminergic activity
had any effects on HR, given that in previous experiments using
sulpiride, we have observed sedative-like effects in mares (personal
observation) and lessening of aggressive male behavior in stallions
before seminal collection [18]. In all ﬁve experiments, changes in
HR in response to bromocriptine, cabergoline, and pergolide were
recorded when horses were standing, walking, and trotting for
2 minutes.
2. Materials and Methods
All procedures described herein were approved by the Institutional Animal Care and Use Committee of the LSU AgCenter. All
horses were long-term residents of the LSU AgCenter Horse Farm in
Baton, Louisiana, and were routinely maintained outdoors on
native grass pastures during the warm seasons and on winter
ryegrass in winter months. Alicia Bermuda grass hay was supplemented as the availability of pasture grass diminished during the
fall and winter months.
Five experiments were performed to study the effects of
commonly used dopaminergic agonists and one antagonist on HR
in horses. Experiments 1 through 3 assessed bromocriptine,
cabergoline, and pergolide, respectively, whereas experiments 4
and 5 assessed changes in HR because of sulpiride administration
under short-term and long-term conditions. All horses used in
these experiments were healthy and free of any ailments. Given
that the aforementioned agents have been extensively documented
to affect prolactin secretion in horses [5,19e25], plasma prolactin
concentrations were used in all experiments as a measure of drug
efﬁcacy.
2.1. Experiment 1: Bromocriptine
A preliminary trial using four Quarter Horse mares was conducted on April 15, 2016, to determine the time point at which
50 mg of bromocriptine dissolved in 1 mL ethanol (200 proof,
Pharmaco-Aaper, Brookﬁeld, CT, USA) administered IV would
maximally suppress prolactin secretion. Fig. 1 illustrates the
maximal suppression (P < .01) of prolactin concentrations 12 hours
after injection. Based on these data, in the evening of April 27, 2016,
six, mature Quarter Horse geldings ranging in age from 7 to 17,
weighing from 480 to 520 kg, and with a body condition score
([BCS]; [26]) between 5 and 7, were brought in from pasture and
pretreated IV with either 50 mg of bromocriptine (n ¼ 3) or vehicle
(1 mL ethanol; n ¼ 3) 12 hours before the execution of the exercise
protocol. All geldings were returned to the pasture until the next
day. The following morning at approximately 0630 hours, all the
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Fig. 1. Mean plasma prolactin concentrations from the preliminary trial in which
mares (n ¼ 4) were administered 50 mg of bromocriptine intravenously at time 0.
Asterisks indicate differences (P < .01) from the time 0 mean concentration. An
appropriate time for bromocriptine treatment was selected as 12 hours before exercise
based on these data. Pooled SEM was 0.7 ng/mL.

geldings were quietly walked from the pasture into an outside
chute. One by one, the horses were taken out of the chute into
covered shed and ﬁtted with a heart rate monitor (Polar Equine
M400 Heart Rate Monitors, Kempele, Finland) attached to a surcingle. Afterward, each horse was walked to an outdoor round pen
and lunged at the trot for 2 minutes. After all horses had been
exercised and samples collected, they were returned to pasture
until the next exercise day. Horses were allowed to rest for 7 days
after which the experimental protocol was repeated with the
treatments reversed (switchback design).
Heart rate was measured in the shed area for 15 minutes before
lunging (resting HR), in the round pen just before lunging, immediately after lunging, and 5 minutes after lunging. Each blood
sample was collected via jugular venipuncture through a 21 G  1inch vacutainer needle into a 6 mL evacuated plastic tube containing K3EDTA (Vacuette, Greiner Bio-One, Monroe, NC, USA)
at 15, 0, 5, 10, 20, and 30 minutes relative to the start of exercise
(trotting in a round pen). All blood samples were immediately
placed in an ice water bath on collection and centrifuged at the end
of the day's experiment in a refrigerated centrifuge at 4 C for
15 minutes at 1200  g. Plasma was transferred to polypropylene
tubes and frozen at 20 C until later analysis.
At the end of the experiment, all frozen blood samples were
thawed and analyzed for prolactin [27] and growth hormone (GH)
[28] concentrations by radioimmunoassay previously validated for
horse plasma. Plasma adrenocorticotropin (ACTH) was measured
by radioimmunoassay with commercially available kit reagents
(MP Biomedicals Inc, Costa Mesa, CA, USA). Estimates of the limit of
detection of the assay and the intra- and interassay coefﬁcient of
variation were 0.2 ng/mL, 7%, and 12% for prolactin, 0.5 ng/mL, 8%
and 11% for GH, and 5.7 pg/mL, 6.8%, and 10.7% for ACTH,
respectively.
Data were analyzed as a replicated Latin square with repeated
measures [29]. Differences between means for each sampling time
were assessed by the pdiff option in SAS (least signiﬁcant difference
comparison) where appropriate.
2.2. Experiment 2: Cabergoline
Ten Quarter Horses were used (ﬁve mares and ﬁve geldings).
They ranged in age from 8 to 21 years, weighed 420e590 kg, and
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had a BCS of 5e7. Horses were randomly assorted into two groups
such that gender, ages, weight, and BCS were similar between
groups. Three mares and geldings were assigned as treatment and
two mares and geldings were assigned as controls. Treatment
consisted of 5 mg of cabergoline (Sigma Chemical Co, St. Louis, MO,
USA) dissolved in 1 mL of vegetable oil (Crisco brand; J.M. Smucker
Co., Orrville, OH, USA) with a few drops of DMSO (Sigma) added in
order for cabergoline to go into solution. Control horses received
1 mL of DMSO/vegetable oil. All treatments were injected intramuscularly (IM) in the neck area.
The experiment was conducted from April 17, 2017 to April 23,
2017. The exercise protocol was the same as described for experiment 1 and was repeated every day, starting on day 0, for six
consecutive days. In this experiment and subsequent experiments,
the heart rate monitor was adjusted to continuously record HR data
to better detect changes in HR while the horses were in motion.
Treatments were administered on day 0 after each horse had
completed their pretreatment exercise bout.
From the continuous heart monitor data, ﬁve data points were
collected: shed (resting HR), walking peak HR, pre-exercise HR,
peak exercise HR, and postexercise HR (immediately after stopping). Jugular blood samples were taken by venipuncture into
evacuated 6 mL EDTA tubes when the horse was at rest in the shed
area (denoted “shed”), before lunging in the round pen ("pre-exercise”), and immediately after lunging (“postexercise”). All blood
samples were processed and assayed for prolactin as described in
experiment 1.
Plasma prolactin and HR data were analyzed by analysis of variance (ANOVA) using the general linear model in SAS (SAS Institute,
Cary, NC, USA). They were analyzed using a double split plot design
with treatment as the main effect, day of experiment as the ﬁrst split,
and multiple sampling times within each day as the second split.
Treatment was tested with the horse within treatment term, day and
day by treatment interaction was tested with the day  horse within
treatment interaction, and sampling time and its interactions were
tested with residual error. Where needed, differences between
treatment groups and individual time period means were tested for
signiﬁcance by the least signiﬁcant difference test [29].
2.3. Experiment 3: Pergolide
Nine horses from experiment 2 were used in this experiment
except for one mare that was withdrawn because of issues unrelated to the previous experiment. One gelding and two mares were
added to this experiment, for a total of 12, six mares and six geldings. Horses were assigned to either treatment or control such that
gender, age, weight, and BCS were fairly equally distributed. Their
ages, weights, and BCS were similar to those in experiment 2. The
experiment was conducted from June 10, 2017 to June 17, 2017.
Because of time limitations, the experiment was carried out in
two equal replicates, staggered by one day. On the ﬁrst day of each
replicate, the horses were exercised, blood samples taken, and HR
monitored as described in experiment 2. After each horse ﬁnished
exercising, they were individually given of 2 mg of pergolide
mesylate (Prascend, Boerhinger Ingelheim Vetmedica Inc., Duluth,
GA, USA) top dressed on 0.23 kg of sweet feed (Crossroads Feeds All
Stock, Purina Animal Nutrition LLC, Shoreview, MN, USA) before
returning back out to pasture. Controls were given only the sweet
feed. Treatment was repeated every day at 0800 hours until day 8,
and exercise was repeated on days 5 and 8. On days 5 and 8, when
treatment and exercise coincided, horses were given their treatment ﬁrst and then allowed to rest for 30 minutes so that treatment
could take effect before starting exercise protocol. Statistical analyses for prolactin and HR were performed as described for
experiment 2.

2.4. Experiment 4: Short-Term Sulpiride Treatment
The same horses used in experiment 3 were used in experiment
4 after a one-week period of no activity. Horses that were treated in
experiment 3 were reassigned as controls and vice versa.
The experiment was conducted from June 24, 2017 to July 2,
2017. Again, due to time restrictions, the experiment was performed in two equal replicates. The exercise protocol was the same
as described in experiment 1, and the blood sampling and heart rate
monitoring were conducted as described in experiment 2 with two
exceptions. Because of the short half-life of sulpiride (Sigma) in
saline, treatment (0.1 mg/kg BW sulpiride as the racemic mixture in
saline, IV, or saline only) was administered immediately after
turning on the heart rate monitor, and each animal was allowed to
rest 10 minutes before proceeding to the round pen. An additional
blood sample and HR data point were taken at 10 minutes post
sulpiride administration and before walking to the round pen. One
week later, on July 1, 2017, treatment groups were switched, and
the experiment was repeated so that each horse served as its own
control.
Heart rate was analyzed as a replicated 2  2 Latin square with
treatment, replicate, horse within replicate, and day within replicate as factors in the ANOVA. Plasma prolactin concentrations were
analyzed as a replicated 2  2 Latin square as the ﬁrst split with
each individual factor tested with the four-way interaction and the
time point and treatment by time point in the second split tested
with the residual.
2.5. Experiment 5: Long-Term Sulpiride Treatment
Experiment 5 began July 5, 2017, 3 days after ﬁnishing experiment 4. Previous research from our lab has shown prolactin levels
return back to baseline 1 hour after sulpiride administration in
saline [30]. Therefore, it was assumed that 3 days of washout period
for treated animals in the previous experiment was sufﬁcient to
attain a proper baseline for the current experiment. Horses that
were assigned as treated in the switchback were reassigned as
controls, and those that were controls were assigned to treatment.
All 12 horses were exercised as described in experiment 1 on
days 1, 2, 3, 7, and 11. Horses were administered 1 g of racemic
sulpiride dissolved in 3 mL of vegetable oil intramuscularly or
vehicle alone, after exercise on day 1 and then again on days 4 and
8. Blood sampling and heart rate monitoring were conducted as
described in experiment 2. Statistical analyses for prolactin and HR
were performed as described for experiment 2.
3. Results
3.1. Experiment 1: Bromocriptine
Mean plasma prolactin concentrations around the time of exercise (12 hours after bromocriptine or vehicle treatment) in
geldings are presented in Fig. 2. Prolactin increased (P < .05) in
response to exercise in control geldings, whereas previous
bromocriptine treatment reduced (P < .01) prolactin concentrations
by 90%; no prolactin response to exercise was noted in this group.
Heart rate increased (P < .001) in controls when they were
walked to the exercise area (Fig. 3.). This increase in HR as they
were walking to the round pen was not seen (P ¼ .12) in
bromocriptine-treated geldings. Moreover, throughout this period,
HR in bromocriptine-treated geldings were lower than controls
(P ¼ .011). Trotting for 2 minutes increased (P < .001) HR in controls
as well as in geldings treated with bromocriptine (Fig. 3.); however,
bromocriptine reduced (P ¼ .0002) the postexercise HR relative to
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Fig. 2. Mean plasma prolactin concentrations in control geldings (vehicle-treated)
during an exercise bout and in geldings previously administered 100 mg of bromocriptine intravenously 12 hours before onset of exercise. Exercise induced a rise in
prolactin concentrations in controls (P < .05), whereas prolactin concentrations after
bromocriptine treatment were suppressed and did not respond to exercise. Pooled
SEM was 1.3 ng/mL.

control bouts. After 5 minutes of recovery, HR decreased (P < .0001)
and was not different (P ¼ .26) between control and treated horses.
Treatment with bromocriptine precluded the exercise-induced
increase (P < .05) in plasma ACTH concentrations observed when
geldings were treated with vehicle (Fig. 4.). Plasma GH concentrations were higher (P < .05) before exercise and at 5 and 10 minutes
after exercise when geldings were treated with bromocriptine
(Fig. 5.), but the magnitude of the exercise-induced responses (P <
.05) was similar for both control and treatment exercise bouts.
3.2. Experiment 2: Cabergoline
Because of inclement weather, no data were collected on day 3
of the experiment. In addition, one mare's prolactin and HR data
were 2e3 times higher than all the other horses and met the criterion as outliers; therefore, her data were excluded from the
analyses.

Fig. 3. Mean heart rates in geldings during control (vehicle-treated) exercise bouts and
during bouts 12 hours after administration of 100 mg of bromocriptine intravenously.
The experiment was performed as a switch-back design; thus, each mean includes 10
data points. Exercise induced a rise in HR in all bouts; HR was lower at time 0 (P ¼ .011)
and immediately after exercise (PE; P ¼ .0002) when geldings were treated with
bromocriptine relative to control bouts (asterisks). Pooled SEM was 7.0 bpm.
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Fig. 4. Mean plasma adrenocorticotropin (ACTH) concentrations in geldings during
control (vehicle-treated) exercise bouts and during bouts 12 hours after administration
of 100 mg of bromocriptine intravenously. The experiment was performed as a switchback design; thus, each mean includes 10 data points. Exercise induced a rise (P < .05)
at 5 minutes in ACTH in control bouts; this rise was not present when geldings
received bromocriptine. *P < .05; þP < .1. Pooled SEM was 4.0 pg/mL.

Mean plasma prolactin concentrations in control and
cabergoline-treated horses are presented in Fig. 6. The treatment by
time interaction for prolactin secretion indicated a near complete
suppression (P < .0001) of prolactin in cabergoline-treated animals,
thereby conﬁrming dopaminergic activity throughout the duration
of the experiment.
Mean HR by day and mean net HR by time point and day in
treated and control horses are presented in Fig. 7. When all time
points for treated and control animals were averaged and
compared by day, the overall response in HR to a short bout of
exercise was reduced signiﬁcantly (P < .05) 24 hours after cabergoline treatment (Fig. 7A). By day 2, overall HR tended to differ
between groups (P ¼ .067), though no more differences were noted
on subsequent days. By chance, the mean initial HR in treated and
control groups before treatment tended to differ (P ¼ .13);

Fig. 5. Mean plasma growth hormone (GH) concentrations in geldings during control
(vehicle-treated) exercise bouts and during bouts 12 hours after administration of
100 mg of bromocriptine intravenously. The experiment was performed as a switchback design; thus each mean includes 10 data points. Exercise induced a rise (P <
.05) in GH in both control bouts and those after bromocriptine treatment. Mean GH
concentrations were higher after bromocriptine treatment than after vehicle treatment; *P < .05; þP < .1. Pooled SEM was 0.7 ng/mL.

124

N. Arana-Valencia et al. / Journal of Equine Veterinary Science 71 (2018) 120e128

more evident (Fig. 7B-F). Cabergoline treatment signiﬁcantly
reduced (P < .05) the response in HR because of physical activity, be
it walking or actively trotting, for at least 5 days.
3.3. Experiment 3: Pergolide

Fig. 6. Mean plasma prolactin concentrations averaged by day in horses administered
5 g of cabergoline in 1 mL of vegetable oil (n ¼ 5) or vehicle (control; n ¼ 4) IM.
Prolactin concentrations were inhibited (P < .0001) in cabergoline-treated horses
relative to day 0 (asterisks). Pooled SEM was 0.35 ng/mL.

therefore, to better detect differences between groups, the mean
net change in HR from day 0 for each treatment group at each time
point was calculated and analyzed in the ANOVA (Fig. 7). When
treatment groups were compared in this manner on each day of the
experiment, changes in HR because of treatment became much

Daily pergolide treatment, administered as a top dressing fed
with sweet feed, inhibited (P < .0001) prolactin secretion in treated
horses compared to control horses through out the sampling period
(Fig. 8). Mean changes in HR after pergolide administration and in
response to an acute bout of exercise are presented in Fig. 9. A day
effect (P ¼ .024) and a day by treatment interaction (P ¼ .02) were
observed at the shed time point (rest). Further analysis with the
least signiﬁcant difference test between day by treatment revealed
a decrease (P ¼ .0002) in HR in treated horses compared to the
control group on day 7. At the walking time point, there was a day
effect (P < .0001) presenting as a downward trend of HR as days
progressed; however, further analysis of the day by treatment
interaction did not reveal signiﬁcant differences when using the
least signiﬁcant difference test. There were no further differences in
HR at each of the other time points.
3.4. Experiment 4: Short-Term Sulpiride Treatment
Mean plasma prolactin concentrations and HR are presented in
Fig. 10. Sulpiride treatment increased (P < .0001) prolactin

Fig. 7. (A) Mean heart rates averaged over all time periods of horses administered 5 mg of cabergoline (n ¼ 5) or vehicle (Controls; n ¼ 5) intramuscularly on day 0 after the exercise
protocol was completed. Differences for each group from its day 0 mean are indicated: þP ¼ .067; *P < .001. Overall SEM ¼ 2.1 bpm. (BeF) Mean net change in HR (relative to
individual day 0 data) of horses administered 5 mg of cabergoline (n ¼ 5) or vehicle (controls; n ¼ 5) intramuscularly on day 0 after the exercise protocol was completed. Heart rates
were assessed in the shed (resting, inactive), then when walking to the round pen, again just before exercise started (pre), at the peak during the 2-minute exercise bout (trotting),
and then immediately after exercise was stopped (post). Mean heart rates averaged over all horses for day 0 were 43.9 in the shed, 92.0 while walking, 56.4 in the pre period, 136.4
at peak rates, and 110.0 in the post period. Differences between groups for each day are indicated: *P < .05; **P < .001. Standard error of the mean for each time point is presented in
each graph.

N. Arana-Valencia et al. / Journal of Equine Veterinary Science 71 (2018) 120e128

125

IM are presented in Fig. 11. Three time points were measured by
day: shed (at rest), pre, and post exercise. Plasma prolactin concentrations increased (P < .0001) in sulpiride-treated animals,
peaking by day 1 then decreasing with time; however, levels
remained elevated compared to controls until the end of the
sampling period on day 11.
Mean HR in response to exercise after administration of sulpiride or vehicle are presented in Fig. 12. Effect of treatment was
compared at each individual time point where HR was monitored
by day. There was no overall effect (P > .1) of sulpiride treatment or
any interaction of treatment by day for any time point. Spurious
differences were noted on day 0 at the shed time point (P ¼ .021)
and on day 11 (P ¼ .01) at the walking time point. These differences
were detected by the least signiﬁcant difference test even though
the main effect of treatment was not signiﬁcant.
Fig. 8. Mean plasma prolactin concentrations before and after a short bout of exercise
in horses administered 2 mg of pergolide (n ¼ 6) or control (n ¼ 6) top dressed over
sweet feed daily for 8 days. Plasma prolactin was assessed on day 0 (before treatment)
and on days 4 and 7 in the shed (resting, inactive), before exercise (pre), and immediately after a 2-minute exercise bout (post). Prolactin was signiﬁcantly inhibited (P <
.0001) in pergolide-treated horses relative to controls, denoted by asterisks, with the
effect lasting till the end of the sampling period. Pooled SEM was 1.30 ng/mL.

concentrations within 10 minutes, which remained elevated for the
entire sampling period, thereby conﬁrming the antidopaminergic
activity of sulpiride. However, mean HR at each site was unaffected
because of sulpiride treatment (P > .1).
3.5. Experiment 5: Long-Term Sulpiride Treatment
Mean plasma prolactin concentrations in control horses and
horses administered 1 g of racemic sulpiride in 1 mL of vegetable oil

4. Discussion
Previous experiments [18,27,28,31e33] have reported rises in
plasma prolactin and GH concentrations when horses are subjected to brief periods of stress, such as 2e5 minutes exercise
bouts, twitching, teasing, and seminal collections (i.e., any activity
that increases HR and ACTH concentrations). Experiment 1 was
initially performed to assess the response of known stresssensitive hormones in a low prolactin environment when horses
were lunged at the trot for 2 minutes. Bromocriptine was chosen
due to 1) its agonistic behavior on D2 dopamine receptors on
prolactin secretion [5] and 2) for its relatively short half-life
compared to cabergoline. The preliminary trial indicated that
intravenous injection of 50 mg of bromocriptine maximally
reduced prolactin concentrations at 12 hours after injection. Based
on this information, the main experiment was performed with

Fig. 9. Mean heart rate before and after a short bout of exercise in horses administered 2 mg of pergolide (n ¼ 6) or control (n ¼ 6) top dressed over sweet feed daily for 8 days.
Short 2-minute exercise bouts were performed on days 0, 4, and 7 and HR was assessed at the shed (rest), walking toward the round pen (walking), immediately before trotting
(pre), peak HR while trotting (peak), and immediately after trotting (post). Differences between groups are marked with an asterisk. For the walking time point, there was a day
effect (P < .0001), denoting a downward trend of HR in both groups; however, no difference between treatment groups were present in the ANOVA. Pooled SEM was 2.7 bpm.
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Fig. 11. Mean plasma prolactin concentrations by day of experiment and time point
(shed, pre, post) in horses after long-term treatment with 1 g of sulpiride (racemic
mixture) or vehicle (control) in 1 mL of vegetable oil in experiment 5. Treatments were
administered on day 0, 4, and 8. Prolactin was higher (P < .0001) in sulpiride-treated
horses than controls, denoted by asterisks, with the effect lasting till the end of the
sampling period. Pooled SEM was 1.11 ng/mL.

Fig. 10. (A) Mean plasma prolactin concentrations before and after a short bout of
exercise in vehicle-treated and short-term sulpiride-treated (.01 mg/kg BW) horses at
rest (shed), 10 minutes after sulpiride or vehicle administration (10 minutes), right
before being lunged at the trot for 2 minutes (pre), and immediately after lunging
(post). The experiment was performed as a single switchback with repeated measures
and analyzed as a replicated 2  2 Latin square in the ﬁrst plot with site and treatment
by site interaction as the split. Concentrations were higher (P < .0001) in treated horses
relative to controls conﬁrming antidopaminergic activity. Asterisks indicate differences
between groups for the designated sampling sites. Pooled SEM was 4.75 ng/mL. (B)
Mean heart rate in control and sulpiride-treated horses at each time point that HR data
was collected. The experiment was performed as a single switchback and analyzed as a
replicated 2  2 Latin square. There was no treatment effect (P > .1) on HR at any given
time point. Pooled SEM was 3.7 bpm.

bromocriptine administered 12 hours before exercise the
following morning. It was found that bromocriptine not only
reduced the exercise-induced rise in HR but also blunted the rise
in exercise-induced prolactin and ACTH secretions as well.
Although the overall response in GH was unaffected because of
treatment, GH tended to be higher in bromocriptine-treated
geldings than controls. In human studies, bromocriptine and
other dopamine agonists have contrasting actions on GH secretion,
in that they are generally stimulatory in healthy individuals but
inhibitory in individuals with abnormal pituitary function
[34e36]. Although this effect has not been previously documented
in the horse, the overall GH response in this experiment was
otherwise unaffected by treatment.
The bradycardic effect of bromocriptine observed in experiment
1 might be explained by its inhibitory action on peripheral sympathetic neurons [12]. Because D2 dopaminergic receptors can be
found at the presynaptic end of sympathetic neurons, activation of
these receptors by bromocriptine can reduce sympathetic tone by

reducing norepinephrine release [11,15]. As a consequence, peripheral blood vessels dilate, which is followed by a decrease in HR,
blood pressure, and peripheral resistance, though cardiac output
generally remain unaffected [8].
In response to these ﬁndings, the question arose as to whether
other dopaminergic agonists might cause the same effect at doses
commonly used in the equine industry. Cabergoline and pergolide
are two commonly used dopamine agonists for the treatment of
PPID in horses. Much success has been met with their application,
and pergolide is currently marketed as the treatment of choice by
veterinarians. However, to our knowledge, no one has reported its
effects on HR because of acute or chronic treatment in horses.
Because experiment 1 was done on one day, any possible effects
on HR carried over to subsequent days could not be determined.
Therefore, for experiments 2 through 5, the acute and chronic effects of the selected agents were assessed. In addition, in each
experiment, the expected suppression of prolactin secretion by the
selected agent was in fact observed, conﬁrming the dopaminergic
activity of the treatments.
Because of the tendency of HR to differ between treatment
groups in experiment 2 (cabergoline treatment), the data for subsequent days were ﬁrst normalized to day 0 data, and the residuals
were analyzed as such. From that analysis, it was determined that
the cabergoline blunting of HR after exercise lasted through day 5 of
the experiment. The blunting effect on HR was only evident in the
time points where each horse was acutely exposed to a stressor, as
in the case of walking to the round pen, trotting, or just ﬁnishing
the 2-minute trot bout but not during periods of inactivity. The
ability of cabergoline to blunt the exercise-induced rise in HR is
likely because of its similar binding afﬁnity to D2 dopaminergic
receptors on presynaptic terminals [37]. In contrast, this reduction
to stress-induced HR was not observed in pergolide treatment,
even though plasma prolactin concentrations were suppressed as
expected. Like bromocriptine and cabergoline, pergolide has a
strong afﬁnity for D2 receptors; so in theory, it should have affected
the D2 receptors located on the presynaptic terminals of sympathetic neurons. It may be possible that sympathetic effects of pergolide were not noticed in this study due to its short-term
treatment. Pergolide is metabolized relatively quickly in horses,
exerting its dopaminergic effects for 12 hours on average [21].
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Fig. 12. Mean heart rate by time point and day of experiment in horses after administration of 1 g of sulpiride (racemic mixture) or vehicle (control) in 1 mL of vegetable oil in
experiment 5. Injections were given in the neck. There was no effect (P > .1) of treatment or interaction of treatment by day at any time point, except where it is noted with an
asterisk. The least signiﬁcant difference for the shed time point on day 0 was P ¼ .021 and P ¼ .01 at the walking time point on day 11. Pooled SEM was 2.5 bpm.

Therefore, a longer-term study with higher doses of pergolide may
be needed to assess its interaction with sympathetic effects in
horses.
In human medicine, sulpiride has been used as antipsychotic,
antiemetic, and antiseptic drug [38]. In past experiments, sedative
effects have been noted in horses 5e10 minutes after sulpiride
administration (N. Arana Valencia and D. L. Thompson, Jr., personal
observations). Thomson et al. [18] also noted a slowing of aggressive male sexual behavior in stallions during seminal collections.
Given the antidopaminergic nature of sulpiride, an effect opposite
of bromocriptine or cabergoline might be expected on HR after
exercise; however, no literature indicating such an effect was found
for any species. Results from experiment 4 (short-term sulpiride)
and 5 (long-term sulpiride) indicated that HR in response to exercise was similar in both treatment groups across all time points. The
acute or chronic antagonistic effects on D2 dopaminergic receptors
had no discernible effects on HR.
In conclusion, administration of bromocriptine and cabergoline
at the doses and modes of administration presented in these experiments signiﬁcantly decreased the exercise-induced rise in HR
in horses. Although the focus in these was on HR, the effect of
bromocriptine on ACTH secretion in the ﬁrst experiment likely
conﬁrms that these drugs mute the sympathetic response to exercise similar to what has been reported for humans, rats, dogs, and
cats [8e13]. The implication of this effect may be of importance for
horses engaged in competitive activities and deserves further
investigation.
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